JP2024515968A5 - - Google Patents
Info
- Publication number
- JP2024515968A5 JP2024515968A5 JP2023565628A JP2023565628A JP2024515968A5 JP 2024515968 A5 JP2024515968 A5 JP 2024515968A5 JP 2023565628 A JP2023565628 A JP 2023565628A JP 2023565628 A JP2023565628 A JP 2023565628A JP 2024515968 A5 JP2024515968 A5 JP 2024515968A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179879P | 2021-04-26 | 2021-04-26 | |
| US63/179,879 | 2021-04-26 | ||
| PCT/US2022/026005 WO2022231978A1 (en) | 2021-04-26 | 2022-04-22 | Anti-gal3 antibody formulations and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515968A JP2024515968A (ja) | 2024-04-11 |
| JPWO2022231978A5 JPWO2022231978A5 (https=) | 2025-04-28 |
| JP2024515968A5 true JP2024515968A5 (https=) | 2025-04-28 |
Family
ID=83848624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565628A Pending JP2024515968A (ja) | 2021-04-26 | 2022-04-22 | 抗ｇａｌ３抗体製剤およびその使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240158512A1 (https=) |
| EP (1) | EP4329804A4 (https=) |
| JP (1) | JP2024515968A (https=) |
| CN (1) | CN117561080A (https=) |
| WO (1) | WO2022231978A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| WO2025064944A1 (en) * | 2023-09-20 | 2025-03-27 | Vor Biopharma Inc. | Anti-cd45 antibody-drug conjugate pharmaceutical compositions |
| CN121263444A (zh) * | 2024-03-08 | 2026-01-02 | 孙氏医药有限公司 | 抗半乳糖凝集素3抗体和其在癫痫和相关疾病中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2018263868A1 (en) * | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| AU2020214796A1 (en) * | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) * | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
-
2022
- 2022-04-22 JP JP2023565628A patent/JP2024515968A/ja active Pending
- 2022-04-22 CN CN202280045350.2A patent/CN117561080A/zh active Pending
- 2022-04-22 WO PCT/US2022/026005 patent/WO2022231978A1/en not_active Ceased
- 2022-04-22 EP EP22796456.6A patent/EP4329804A4/en active Pending
-
2023
- 2023-10-23 US US18/492,607 patent/US20240158512A1/en active Pending